# VCEL — Vericel Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VCEL  
**Sources:** 27  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-vcel-vericel-corp-catalysts-narrative-risks-9630

---

# Vericel Corp (NASDAQ: VCEL) — Research Snapshot as of October 27, 2026

## Company Profile (brief)
Vericel is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets, headquartered in Cambridge, Massachusetts, and formerly known as Aastrom Biosciences [[25]](https://www.vcel.com/about/), [[26]](https://en.wikipedia.org/wiki/Vericel). It markets three U.S. products: MACI (cartilage repair), Epicel (burn skin replacement), and NexoBrid (eschar removal, licensed from MediWound) [[3]](https://www.advfn.com/stock-market/NASDAQ/VCEL/stock-news/99011409/vericel-reports-second-quarter-2026-financial-resu), [[24]](https://www.vcel.com/). The stock trades near ~$43 with a market cap of ~$2.2B and ~51.2M shares; its 52-week range is $28.95–$49.32, with YTD +19.5% and 1-year +18.5% returns [[10]](https://tickernerd.com/stock/vcel-forecast/), [[27]](https://stockanalysis.com/stocks/vcel/). Valuation is rich: a P/E (TTM) of ~92 and forward PE of ~66 [[27]](https://stockanalysis.com/stocks/vcel/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-vcel-vericel-corp-catalysts-narrative-risks-9630 (free to sign up)._